MARKET

ANVS

ANVS

Annovis Bio Inc
NYSE
2.120
+0.150
+7.61%
Opening 12:41 07/07 EDT
OPEN
1.945
PREV CLOSE
1.970
HIGH
2.120
LOW
1.920
VOLUME
742.38K
TURNOVER
--
52 WEEK HIGH
5.50
52 WEEK LOW
1.541
MARKET CAP
90.19M
P/E (TTM)
-1.2435
1D
5D
1M
3M
1Y
5Y
1D
Annovis Bio announces full enrollment for buntanetap trial
TipRanks · 5h ago
Annovis Bio Announces Full Enrollment Of Its Phase 3 Trial Of Buntanetap In Patients With Early Alzheimer’s Disease; The Trial Enrolled 850 Patients; Symptomatic Data Readout Expected In Q1 2027, and Disease-Modifying Data Readout Anticipated in Q1 2028
Benzinga · 5h ago
Weekly Report: what happened at ANVS last week (0629-0703)?
Weekly Report · 1d ago
Press Release: Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
Dow Jones · 6d ago
Weekly Report: what happened at ANVS last week (0622-0626)?
Weekly Report · 06/29 09:03
Weekly Report: what happened at ANVS last week (0615-0619)?
Weekly Report · 06/22 09:04
Annovis Bio Shareholders Approve Governance and Compensation Changes
TipRanks · 06/17 22:35
Weekly Report: what happened at ANVS last week (0608-0612)?
Weekly Report · 06/15 09:04
More
About ANVS
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.

Webull offers Annovis Bio Inc stock information, including NYSE: ANVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANVS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANVS stock methods without spending real money on the virtual paper trading platform.